6o3j › Citations

An MPER antibody neutralizes HIV-1 using germline features shared among donors.

Fig. 1
Fig. 2
Fig. 3
Zhang L, Irimia A, He L, Landais E, Rantalainen K, Leaman DP, Vollbrecht T, Stano A, Sands DI, Kim AS, Poignard P, Burton DR, Murrell B, Ward AB, Zhu J, Wilson IA, Zwick MB
OpenAccess logo Nat Commun 10 5389 (2019)
Related entries: 6o3d, 6o3g, 6o3k, 6o3l, 6o3u, 6o41, 6o42

Cited: 31 times
EuropePMC logo PMID: 31772165

Abstract

The membrane-proximal external region (MPER) of HIV-1 envelope glycoprotein (Env) can be targeted by neutralizing antibodies of exceptional breadth. MPER antibodies usually have long, hydrophobic CDRH3s, lack activity as inferred germline precursors, are often from the minor IgG3 subclass, and some are polyreactive, such as 4E10. Here we describe an MPER broadly neutralizing antibody from the major IgG1 subclass, PGZL1, which shares germline V/D-region genes with 4E10, has a shorter CDRH3, and is less polyreactive. A recombinant sublineage variant pan-neutralizes a 130-isolate panel at 1.4 μg/ml (IC50). Notably, a germline revertant with mature CDR3s neutralizes 12% of viruses and still binds MPER after DJ reversion. Crystal structures of lipid-bound PGZL1 variants and cryo-EM reconstruction of an Env-PGZL1 complex reveal how these antibodies recognize MPER and viral membrane. Discovery of common genetic and structural elements among MPER antibodies from different patients suggests that such antibodies could be elicited using carefully designed immunogens.

Articles - 6o3j mentioned but not cited (1)

  1. Dynamic HIV-1 spike motion creates vulnerability for its membrane-bound tripod to antibody attack. Yang S, Hiotis G, Wang Y, Chen J, Wang JH, Kim M, Reinherz EL, Walz T. Nat Commun 13 6393 (2022)


Reviews citing this publication (9)

  1. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Ng'uni T, Chasara C, Ndhlovu ZM. Front Immunol 11 590780 (2020)
  2. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, McMichael AJ, Kelsoe G, Hahn BH, Alt F, Shaw GM. Nat Rev Immunol 23 142-158 (2023)
  3. Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. Spencer DA, Shapiro MB, Haigwood NL, Hessell AJ. Front Public Health 9 690017 (2021)
  4. HIV vaccinology: 2021 update. Lee JH, Crotty S. Semin Immunol 51 101470 (2021)
  5. Neutralizing Antibodies Targeting HIV-1 gp41. Caillat C, Guilligay D, Sulbaran G, Weissenhorn W. Viruses 12 E1210 (2020)
  6. A Structural Update of Neutralizing Epitopes on the HIV Envelope, a Moving Target. Parker Miller E, Finkelstein MT, Erdman MC, Seth PC, Fera D. Viruses 13 1774 (2021)
  7. HIV-1 Entry and Prospects for Protecting against Infection. Bruxelle JF, Trattnig N, Mureithi MW, Landais E, Pantophlet R. Microorganisms 9 228 (2021)
  8. Lassa virus glycoprotein complex review: insights into its unique fusion machinery. Pennington HN, Lee J. Biosci Rep 42 BSR20211930 (2022)
  9. Significance of Conserved Regions in Coronavirus Spike Protein for Developing a Novel Vaccine against SARS-CoV-2 Infection. Olukitibi TA, Ao Z, Warner B, Unat R, Kobasa D, Yao X. Vaccines (Basel) 11 545 (2023)

Articles citing this publication (21)

  1. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic. Shah P, Canziani GA, Carter EP, Chaiken I. Front Immunol 12 637651 (2021)
  2. HIV-1 Envelope and MPER Antibody Structures in Lipid Assemblies. Rantalainen K, Berndsen ZT, Antanasijevic A, Schiffner T, Zhang X, Lee WH, Torres JL, Zhang L, Irimia A, Copps J, Zhou KH, Kwon YD, Law WH, Schramm CA, Verardi R, Krebs SJ, Kwong PD, Doria-Rose NA, Wilson IA, Zwick MB, Yates JR, Schief WR, Ward AB. Cell Rep 31 107583 (2020)
  3. A cross-neutralizing antibody between HIV-1 and influenza virus. Lee CD, Watanabe Y, Wu NC, Han J, Kumar S, Pholcharee T, Seabright GE, Allen JD, Lin CW, Yang JR, Liu MT, Wu CY, Ward AB, Crispin M, Wilson IA. PLoS Pathog 17 e1009407 (2021)
  4. A VH1-69 antibody lineage from an infected Chinese donor potently neutralizes HIV-1 by targeting the V3 glycan supersite. Kumar S, Ju B, Shapero B, Lin X, Ren L, Zhang L, Li D, Zhou Z, Feng Y, Sou C, Mann CJ, Hao Y, Sarkar A, Hou J, Nunnally C, Hong K, Wang S, Ge X, Su B, Landais E, Sok D, Zwick MB, He L, Zhu J, Wilson IA, Shao Y. Sci Adv 6 eabb1328 (2020)
  5. Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops. Boughter CT, Borowska MT, Guthmiller JJ, Bendelac A, Wilson PC, Roux B, Adams EJ. Elife 9 e61393 (2020)
  6. Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments. Rujas E, Insausti S, Leaman DP, Carravilla P, González-Resines S, Monceaux V, Sánchez-Eugenia R, García-Porras M, Iloro I, Zhang L, Elortza F, Julien JP, Saéz-Cirión A, Zwick MB, Eggeling C, Ojida A, Domene C, Caaveiro JMM, Nieva JL. Cell Rep 32 108037 (2020)
  7. N-terminal Transmembrane-Helix Epitope Tag for X-ray Crystallography and Electron Microscopy of Small Membrane Proteins. McIlwain BC, Erwin AL, Davis AR, Ben Koff B, Chang L, Bylund T, Chuang GY, Kwong PD, Ohi MD, Lai YT, Stockbridge RB. J Mol Biol 433 166909 (2021)
  8. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. Spencer DA, Malherbe DC, Vázquez Bernat N, Ádori M, Goldberg B, Dambrauskas N, Henderson H, Pandey S, Cheever T, Barnette P, Sutton WF, Ackerman ME, Kobie JJ, Sather DN, Karlsson Hedestam GB, Haigwood NL, Hessell AJ. J Immunol 206 999-1012 (2021)
  9. Histone H2A-Reactive B Cells Are Functionally Anergic in Healthy Mice With Potential to Provide Humoral Protection Against HIV-1. Agazio A, Cimons J, Shotts KM, Guo K, Santiago ML, Pelanda R, Torres RM. Front Immunol 11 1565 (2020)
  10. Membrane Env Liposomes Facilitate Immunization with Multivalent Full-Length HIV Spikes. Leaman DP, Stano A, Chen Y, Zhang L, Zwick MB. J Virol 95 e0000521 (2021)
  11. Molecular recognition of a membrane-anchored HIV-1 pan-neutralizing epitope. Torralba J, de la Arada I, Partida-Hanon A, Rujas E, Arribas M, Insausti S, Valotteau C, Valle J, Andreu D, Caaveiro JMM, Jiménez MA, Apellániz B, Redondo-Morata L, Nieva JL. Commun Biol 5 1265 (2022)
  12. Unique genotypic features of HIV-1 C gp41 membrane proximal external region variants during pregnancy relate to mother-to-child transmission via breastfeeding. Yin L, Chang KF, Nakamura KJ, Kuhn L, Aldrovandi GM, Goodenow MM. J Clin Pediatr Neonatol 1 9-20 (2021)
  13. Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents. Wang Z, Li D, Chen Y, Sun Y, Jin C, Hu C, Feng Y, Su J, Ren L, Hao Y, Wang S, Zhu M, Liu Y, Qi J, Zhu B, Shao Y. Front Immunol 14 1160283 (2023)
  14. Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies. Scheepers C, Kgagudi P, Mzindle N, Gray ES, Moyo-Gwete T, Lambson BE, Oosthuysen B, Mabvakure B, Garrett NJ, Abdool Karim SS, Morris L, Moore PL. PLoS Pathog 18 e1010450 (2022)
  15. Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies. Kim S, Filsinger Interrante MV, Kim PS. J Virol 97 e0164722 (2023)
  16. Focal accumulation of aromaticity at the CDRH3 loop mitigates 4E10 polyreactivity without altering its HIV neutralization profile. Rujas E, Leaman DP, Insausti S, Carravilla P, García-Porras M, Largo E, Morillo I, Sánchez-Eugenia R, Zhang L, Cui H, Iloro I, Elortza F, Julien JP, Eggeling C, Zwick MB, Caaveiro JMM, Nieva JL. iScience 24 102987 (2021)
  17. Functional Delineation of a Protein-Membrane Interaction Hotspot Site on the HIV-1 Neutralizing Antibody 10E8. Insausti S, Garcia-Porras M, Torralba J, Morillo I, Ramos-Caballero A, de la Arada I, Apellaniz B, Caaveiro JMM, Carravilla P, Eggeling C, Rujas E, Nieva JL. Int J Mol Sci 23 10767 (2022)
  18. Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility. Tan K, Chen J, Kaku Y, Wang Y, Donius L, Khan RA, Li X, Richter H, Seaman MS, Walz T, Hwang W, Reinherz EL, Kim M. Nat Commun 14 7218 (2023)
  19. Neutralization Sensitivity and Evolution of Virus in a Chronic HIV-1 Clade B Infected Patient with Neutralizing Activity against Membrane-Proximal External Region. Tang W, Yuan Z, Wang Z, Ren L, Li D, Wang S, Hao Y, Li J, Shen X, Ruan Y, Shao Y, Liu Y. Pathogens 12 497 (2023)
  20. Partial compartmentalisation of HIV-1 subtype C between lymph nodes, peripheral blood mononuclear cells and plasma. Jeewanraj N, Mandizvo T, Mulaudzi T, Gumede N, Ndhlovu Z, Ndung'u T, Gounder K, Mann J. Virology 582 62-70 (2023)
  21. Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. Cai F, Chen WH, Wu W, Jones JA, Choe M, Gohain N, Shen X, LaBranche C, Eaton A, Sutherland L, Lee EM, Hernandez GE, Wu NR, Scearce R, Seaman MS, Moody MA, Santra S, Wiehe K, Tomaras GD, Wagh K, Korber B, Bonsignori M, Montefiori DC, Haynes BF, de Val N, Joyce MG, Saunders KO. PLoS Pathog 17 e1009624 (2021)


Quick links